Eventide Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Eventide Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-359,000	Closed	-$16.8M	–	168
2024 Q1	$16.8M	Hold	359,000	–	–	0.26%	103
2023 Q4	$17.2M	Hold	359,000	–	–	0.28%	92
2023 Q3	$12.8M	Hold	359,000	–	–	0.23%	113
2023 Q2	$16.6M	Hold	359,000	–	–	0.28%	95
2023 Q1	$14.4M	Hold	359,000	–	–	0.26%	103
2022 Q4	$16.6M	Buy	359,000 +53,200	+17%	+$2.09M	0.33%	89
2022 Q3	$12.7M	Buy	+305,800	New	+$15.7M	0.25%	97
2018 Q4	–	Sell	-87,400	Closed	-$6.67M	–	146
2018 Q3	$6.67M	Hold	87,400	–	–	0.25%	94
2018 Q2	$6.72M	Hold	87,400	–	–	0.28%	87
2018 Q1	$4.46M	Hold	87,400	–	–	0.21%	91
2017 Q4	$4.05M	Hold	87,400	–	–	0.21%	89
2017 Q3	$4.66M	Hold	87,400	–	–	0.26%	79
2017 Q2	$5.43M	Hold	87,400	–	–	0.34%	68
2017 Q1	$5.92M	Hold	87,400	–	–	0.39%	67
2016 Q4	$6.14M	Hold	87,400	–	–	0.4%	64
2016 Q3	$6.2M	Hold	87,400	–	–	0.38%	69
2016 Q2	$4.28M	Hold	87,400	–	–	0.26%	75
2016 Q1	$5.53M	Hold	87,400	–	–	0.31%	71
2015 Q4	$9.8M	Sell	87,400 -18,100	-17%	-$1.81M	0.49%	57
2015 Q3	$10.2M	Buy	105,500 +21,400	+25%	+$2.45M	0.59%	52
2015 Q2	$8.61M	Buy	84,100 +15,100	+22%	+$1.17M	0.47%	59
2015 Q1	$4.28M	Buy	69,000 +16,400	+31%	+$911K	0.32%	73
2014 Q4	$2.31M	Hold	52,600	–	–	0.25%	76
2014 Q3	$2.98M	Hold	52,600	–	–	0.42%	64
2014 Q2	$2.36M	Buy	+52,600	New	+$2.17M	0.32%	71

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Eventide Asset Management's RARE Position: Q2 2024 in Review

Eventide Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 359,000 shares — an estimated $16.8M sold.

Eventide Asset Management first reported a position in RARE in Q2 2014 and held it in 25 quarters. The position peaked at $17.2M in Q4 2023. 274 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

Eventide Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Eventide Asset Management sold 359,000 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $16.8M.
Eventide Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2014 and held it in 25 quarters.
Eventide Asset Management's Ultragenyx Pharmaceutical position peaked at $17.2M in Q4 2023.
274 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Eventide Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.